Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Gyre Therapeutics ( (GYRE) ) has provided an announcement.
Gyre Therapeutics announced the resignation of Ying Luo, Ph.D., from his roles as Chairman and board member to focus on other responsibilities at GNI Group Ltd. The company appointed Ping Zhang as a new director, bringing his extensive financial expertise to the board. This move is seen as a strategic step as the company enters a transformative phase, with the leadership change expected to enhance its governance and operational focus. Additionally, Songjiang Ma was appointed as the Chairman of Gyre Pharmaceuticals, signaling a shift in leadership to navigate upcoming challenges and opportunities.
More about Gyre Therapeutics
Gyre Therapeutics is a biopharmaceutical company based in San Diego, focusing on the development and commercialization of treatments for chronic organ diseases, particularly MASH-associated fibrosis. The company is advancing its flagship product, F351, through clinical trials in the U.S. and China, and has a diverse drug pipeline through its subsidiary, Gyre Pharmaceuticals, which includes treatments for various fibrosis-related conditions.
YTD Price Performance: -10.08%
Average Trading Volume: 87,076
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $926M
Learn more about GYRE stock on TipRanks’ Stock Analysis page.
